Javad Mahmoudi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Javad Mahmoudi has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Saeed Sadigh-Eteghad
Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran
35 shared publications Fereshteh Farajdokht
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
13 shared publications- Mehdi Farhoudi
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
11 shared publications Saeed Sadigh-Eteghad
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
11 shared publications- Alireza Majdi
Research Group Experimental Oto-rhino-laryngology, Department of Neuroscience, Leuven Brain Institute, KU Leuven, Leuven, 3000, Belgium
8 shared publications Mahnaz Talebi
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
8 shared publications
Latest Publications
- 19 October 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Sericin improves age-related copulatory impairment in rats through testosterone enhancement and PI3K/Akt/eNOS signaling modulation
Purpose Impaired sexual behavior associated with aging remains a significant global health concern. Studies are investigating natural compounds to identify effective interventions for counteracting this condition. The present study examined the effectiveness of sericin (Ser) on age-related sexual impairment in aged rats. Methods A total of 10 young adult and 40 aged male Wistar rats were used. The aged animals were categorized into four groups and received NS or Ser at doses of 200, 250, and 300 mg/kg for 30 consecutive days. Copulatory behavior was assessed to evaluate sexual function. At the end of the behavioral assessment, serum testosterone levels, penile p-PI3K/PI3K, p-Akt/Akt, p-eNOS/eNOS, and p-NF-κB/NF-κB ratios, oxidative stress markers (TAC, MDA, GPx, and SOD), as well as cGMP, NO, IL-6 and TNF-α levels were measured. Notably, biochemical evaluations (n = 6/group) and Western blotting (n = 3/group) were conducted on representative subsets. Results The results demonstrated that Ser improved copulatory behavior in aged animals. The enhancement in sexual behavior was associated with increased PI3K/Akt/eNOS signaling and restoration of the NO/cGMP pathway, elevated testosterone levels, reduced lipid peroxidation, increased TAC and antioxidant enzyme activities, as well as diminished penile levels of IL-6 and TNF-α in aged rats. Conclusion These findings suggest that the ability of Ser to attenuate oxidative stress and inflammation may represent a promising approach for restoring testosterone levels and PI3K/Akt/eNOS signaling, thereby alleviating age-related sexual dysfunction. Nevertheless, further studies are required to clarify the mechanisms and evaluate therapeutic potential of Ser in the management of sexual dysfunction associated with aging.
- 19 October 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Sericin improves age-related copulatory impairment in rats through testosterone enhancement and PI3K/Akt/eNOS signaling modulation
Purpose Impaired sexual behavior associated with aging remains a significant global health concern. Studies are investigating natural compounds to identify effective interventions for counteracting this condition. The present study examined the effectiveness of sericin (Ser) on age-related sexual impairment in aged rats. Methods A total of 10 young adult and 40 aged male Wistar rats were used. The aged animals were categorized into four groups and received NS or Ser at doses of 200, 250, and 300 mg/kg for 30 consecutive days. Copulatory behavior was assessed to evaluate sexual function. At the end of the behavioral assessment, serum testosterone levels, penile p-PI3K/PI3K, p-Akt/Akt, p-eNOS/eNOS, and p-NF-κB/NF-κB ratios, oxidative stress markers (TAC, MDA, GPx, and SOD), as well as cGMP, NO, IL-6 and TNF-α levels were measured. Notably, biochemical evaluations (n = 6/group) and Western blotting (n = 3/group) were conducted on representative subsets. Results The results demonstrated that Ser improved copulatory behavior in aged animals. The enhancement in sexual behavior was associated with increased PI3K/Akt/eNOS signaling and restoration of the NO/cGMP pathway, elevated testosterone levels, reduced lipid peroxidation, increased TAC and antioxidant enzyme activities, as well as diminished penile levels of IL-6 and TNF-α in aged rats. Conclusion These findings suggest that the ability of Ser to attenuate oxidative stress and inflammation may represent a promising approach for restoring testosterone levels and PI3K/Akt/eNOS signaling, thereby alleviating age-related sexual dysfunction. Nevertheless, further studies are required to clarify the mechanisms and evaluate therapeutic potential of Ser in the management of sexual dysfunction associated with aging.
- 11 July 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Anti-Apoptotic Effects of Sericin in Lumbar Canal Stenosis-Induced Underactive Bladder Model
Purpose: Underactive bladder (UAB) is a challenging urological condition lacking effective pharmacological treatments. While silk sericin has demonstrated anti-apoptotic properties in other tissues, its application in bladder dysfunction remains unexplored. This study investigated the effect of silk sericin on apoptotic markers and urodynamic outcomes in a lumbar canal stenosis (LCS)-induced rat model of UAB, with the novelty centered on evaluating sericin's therapeutic potential specifically in bladder tissue. Methods: Thirty-six female Wistar rats were randomized into six groups: control, sham, UAB model (LCS+normal saline), and LCS+sericin (200, 250, or 300 mg/kg/day, orally for 14 days). UAB was induced via LCS by insertion of silicone rubber at L5–L6. Bladder function was assessed by awake urodynamics, bladder weight, and Western blotting of apoptotic proteins (Bax, Bcl-2, caspase-3, caspase-9). Outcome assessments were performed blinded to treatment group. Representative urodynamic tracings were obtained for each group. Results: Urodynamic evaluation showed significant improvement limited to the intercontraction interval (ICI), which significantly improved with sericin 300 mg compared with LCS (p=0.041). No significant improvements were observed in other urodynamic parameters, including peak pressure, contraction amplitude, or contraction frequency. Bladder weight was significantly increased in LCS rats (indicating possible hypertrophy or edema) and was significantly reduced in the sericin 300 mg group versus LCS (p=0.004). Apoptotic markers Bax and cleaved caspase-3/procaspase-3 decreased significantly with sericin, whereas Bcl-2 expression increased. The most pronounced effects were observed at 300 mg/kg. Conclusion: Sericin demonstrated anti-apoptotic and partial functional protective effects (limited to ICI) in the LCS-induced UAB model, particularly at 300 mg/kg. However, dissociation between apoptotic modulation and functional recovery indicates that anti-apoptotic mechanisms alone may be insufficient to restore detrusor contractility. These preliminary findings suggest sericin as a candidate requiring further investigation, though extensive mechanistic, pharmacokinetic, and long-term studies with histological validation are warranted before translational consideration.
- 11 July 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Anti-Apoptotic Effects of Sericin in Lumbar Canal Stenosis-Induced Underactive Bladder Model
Purpose: Underactive bladder (UAB) is a challenging urological condition lacking effective pharmacological treatments. While silk sericin has demonstrated anti-apoptotic properties in other tissues, its application in bladder dysfunction remains unexplored. This study investigated the effect of silk sericin on apoptotic markers and urodynamic outcomes in a lumbar canal stenosis (LCS)-induced rat model of UAB, with the novelty centered on evaluating sericin's therapeutic potential specifically in bladder tissue. Methods: Thirty-six female Wistar rats were randomized into six groups: control, sham, UAB model (LCS+normal saline), and LCS+sericin (200, 250, or 300 mg/kg/day, orally for 14 days). UAB was induced via LCS by insertion of silicone rubber at L5–L6. Bladder function was assessed by awake urodynamics, bladder weight, and Western blotting of apoptotic proteins (Bax, Bcl-2, caspase-3, caspase-9). Outcome assessments were performed blinded to treatment group. Representative urodynamic tracings were obtained for each group. Results: Urodynamic evaluation showed significant improvement limited to the intercontraction interval (ICI), which significantly improved with sericin 300 mg compared with LCS (p=0.041). No significant improvements were observed in other urodynamic parameters, including peak pressure, contraction amplitude, or contraction frequency. Bladder weight was significantly increased in LCS rats (indicating possible hypertrophy or edema) and was significantly reduced in the sericin 300 mg group versus LCS (p=0.004). Apoptotic markers Bax and cleaved caspase-3/procaspase-3 decreased significantly with sericin, whereas Bcl-2 expression increased. The most pronounced effects were observed at 300 mg/kg. Conclusion: Sericin demonstrated anti-apoptotic and partial functional protective effects (limited to ICI) in the LCS-induced UAB model, particularly at 300 mg/kg. However, dissociation between apoptotic modulation and functional recovery indicates that anti-apoptotic mechanisms alone may be insufficient to restore detrusor contractility. These preliminary findings suggest sericin as a candidate requiring further investigation, though extensive mechanistic, pharmacokinetic, and long-term studies with histological validation are warranted before translational consideration.
- 29 June 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Sericin improves cognitive outcomes in a mouse model of cerebral ischemia: The role of Blood-Brain Barrier disruption and edema
Purpose: Oxidative stress, edema, and blood-brain barrier (BBB) dysfunction are involved in the pathophysiology of stroke and may offer opportunities for managing its related insults. Sericin (Ser) has neuroprotective and pro-cognitive effects. This study aimed to determine whether Ser could reduce cerebral edema and its associated molecular and cognitive abnormalities in a mouse model of cortical ischemia. Methods:The mice were allocated into five cohorts: Sham, normal saline (NS), Ser200, Ser300, and Ser400. Each group received its treatment for 14 days before being subjected to cerebral ischemia or a sham surgery procedure. Spatial memory was assessed using the Lashley III maze. Brain edema, BBB permeability, malondialdehyde (MDA) level, and changes in anti-oxidant markers (total antioxidant capacity (TAC) levels, as well as superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities) were evaluated in the brain samples. Additionally, the expression of BBB structural integrity proteins, including occludin and zonula occludens-1 (ZO-1), and matrix metalloproteinase-9 (MMP-9), were analyzed. Results: Ser300 and Ser400 improved spatial memory (at least p< 0.05). Also, Ser400 reduced brain water content (p< 0.05), Ser300 and 400 decresed BBB leakage (at least p< 0.05), and normalized anti-oxidant markers (at least p< 0.05). As well, Ser400 diminished MDA content (p< 0.05). All doses decreased MMP-9 levels (at least p< 0.01). Ser400 upregulated the expression of occludin (p< 0.01), and Ser300 and 400 increased ZO-1 proteins (at least p< 0.05). Conclusion: Ser improved cognitive dysfunction associated with BBB damage and edema induced by cerebral ischemia in a mouse model.
- 29 June 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Sericin improves cognitive outcomes in a mouse model of cerebral ischemia: The role of Blood-Brain Barrier disruption and edema
Purpose: Oxidative stress, edema, and blood-brain barrier (BBB) dysfunction are involved in the pathophysiology of stroke and may offer opportunities for managing its related insults. Sericin (Ser) has neuroprotective and pro-cognitive effects. This study aimed to determine whether Ser could reduce cerebral edema and its associated molecular and cognitive abnormalities in a mouse model of cortical ischemia. Methods:The mice were allocated into five cohorts: Sham, normal saline (NS), Ser200, Ser300, and Ser400. Each group received its treatment for 14 days before being subjected to cerebral ischemia or a sham surgery procedure. Spatial memory was assessed using the Lashley III maze. Brain edema, BBB permeability, malondialdehyde (MDA) level, and changes in anti-oxidant markers (total antioxidant capacity (TAC) levels, as well as superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities) were evaluated in the brain samples. Additionally, the expression of BBB structural integrity proteins, including occludin and zonula occludens-1 (ZO-1), and matrix metalloproteinase-9 (MMP-9), were analyzed. Results: Ser300 and Ser400 improved spatial memory (at least p< 0.05). Also, Ser400 reduced brain water content (p< 0.05), Ser300 and 400 decresed BBB leakage (at least p< 0.05), and normalized anti-oxidant markers (at least p< 0.05). As well, Ser400 diminished MDA content (p< 0.05). All doses decreased MMP-9 levels (at least p< 0.01). Ser400 upregulated the expression of occludin (p< 0.01), and Ser300 and 400 increased ZO-1 proteins (at least p< 0.05). Conclusion: Ser improved cognitive dysfunction associated with BBB damage and edema induced by cerebral ischemia in a mouse model.
- Open Access
- 26 May 2026
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 48 (2) , 154-165
Effects of hydroalcoholic extract of Melissa officinalis on anxiety-like behavior and oxidative stress markers in the hippocampus of aged mice
Background. The increasing prevalence of mood disorders among the elderly, together with the growing interest in medicinal plants and complementary therapies, highlights the need for further research in this field. The present study investigated the effects of the hydroalcoholic extract of Melissa officinalis on anxiety-like behavior and oxidative stress parameters in the hippocampus of aged mice. Methods. In this study, a total of 45 male albino mice were used, including young (2 months old) and aged (24 months old) animals. The animals in the aged intervention group received Melissa officinalis extract orally at a dose of 150 mg/kg body weight per day, while the aged and young control groups received normal saline orally for 14 days. At the end of the treatment period, behavioral assessments, including the Open Field Test and the Elevated Plus Maze, were performed. In addition, serum corticosterone levels, total antioxidant capacity, and hippocampal levels of malondialdehyde, superoxide dismutase, and glutathione peroxidase were measured. Results. Anxiety-like behavior was significantly increased in the aged control group compared with the young control group (P<0.001). This change was accompanied by elevated serum corticosterone levels, increased malondialdehyde concentrations, and reduced antioxidant enzyme activities in the hippocampus (P<0.01). Administration of the extract significantly improved anxiety-like behavior (P<0.01) and reduced serum corticosterone levels (P<0.05) in the intervention group compared with the aged control group. Moreover, treatment with the extract resulted in reduced malondialdehyde levels (P<0.01) and improved antioxidant enzyme activities (P<0.05). Conclusion. Overall, the findings suggest that the anxiolytic effects of Melissa officinalis in aged mice are mediated, at least in part, through attenuation of stress axis activity, reduction of oxidative stress, and enhancement of hippocampal antioxidant status. Practical Implications. The use of Melissa officinalis extract may exert anxiolytic effects in the elderly by improving hippocampal antioxidant defenses.
- 26 May 2026
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 48 (2) , 154-165
Open AccessEffects of hydroalcoholic extract of Melissa officinalis on anxiety-like behavior and oxidative stress markers in the hippocampus of aged mice
Background. The increasing prevalence of mood disorders among the elderly, together with the growing interest in medicinal plants and complementary therapies, highlights the need for further research in this field. The present study investigated the effects of the hydroalcoholic extract of Melissa officinalis on anxiety-like behavior and oxidative stress parameters in the hippocampus of aged mice. Methods. In this study, a total of 45 male albino mice were used, including young (2 months old) and aged (24 months old) animals. The animals in the aged intervention group received Melissa officinalis extract orally at a dose of 150 mg/kg body weight per day, while the aged and young control groups received normal saline orally for 14 days. At the end of the treatment period, behavioral assessments, including the Open Field Test and the Elevated Plus Maze, were performed. In addition, serum corticosterone levels, total antioxidant capacity, and hippocampal levels of malondialdehyde, superoxide dismutase, and glutathione peroxidase were measured. Results. Anxiety-like behavior was significantly increased in the aged control group compared with the young control group (P<0.001). This change was accompanied by elevated serum corticosterone levels, increased malondialdehyde concentrations, and reduced antioxidant enzyme activities in the hippocampus (P<0.01). Administration of the extract significantly improved anxiety-like behavior (P<0.01) and reduced serum corticosterone levels (P<0.05) in the intervention group compared with the aged control group. Moreover, treatment with the extract resulted in reduced malondialdehyde levels (P<0.01) and improved antioxidant enzyme activities (P<0.05). Conclusion. Overall, the findings suggest that the anxiolytic effects of Melissa officinalis in aged mice are mediated, at least in part, through attenuation of stress axis activity, reduction of oxidative stress, and enhancement of hippocampal antioxidant status. Practical Implications. The use of Melissa officinalis extract may exert anxiolytic effects in the elderly by improving hippocampal antioxidant defenses.
- 5 January 2026
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 32 (1) , 110-120
Melissa officinalis Alleviates Cognitive Impairments in a Mouse Model of Accelerated Aging; Possible Involvement of the Hippocampal Sirt-1/Nrf2/NF-κB Signaling Pathway
Background: Aging is associated with a wide range of cognitive impairments that affect the quality of life in the elderly. This study aimed to assess the neuroprotective properties of the hydro-alcoholic extract of Melissa officinalis L. (HAEMO) on cognitive impairment mediated by the D-galactose/AlCl₃-induced accelerated aging model. Methods: The C57BL/6 mice were allocated into young and aged control groups, and three aged groups received different doses of HAEMO for 60 days. The performance of mice was assessed using the Lashley III maze and the novel object recognition test to assess cognitive function. Hippocampal tissue was examined not only for oxidative stress indicators (TAC, MDA, GPx and SOD) but also used for estimations of Sirt-1, Nrf2, NF-кB, IL-6, and TNF-α proteins. Results: The results indicated improved spatial and recognition memories in the HAEMO-received aged animals. The behavioral advantages were probably linked to diminished lipid peroxidation, increased antioxidant enzyme activities, and enhancement of the hippocampal Sirt-1/Nrf2 pathway. Moreover, the HAEMO regimen reduced inflammatory markers (NF-κB, TNF-α, and IL-6) in the hippocampus. Conclusion: HAEMO exerts a modulatory effect on the hippocampal Sirt-1/Nrf2/NF-κB pathway, offering a neuroprotective approach against progressive oxidative stress and neuroinflammation that develop with aging. Additional research is necessary to completely understand the therapeutic potential of HAEMO in the preservation of cognition during aging.
- 5 January 2026
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 32 (1) , 110-120
Melissa officinalis Alleviates Cognitive Impairments in a Mouse Model of Accelerated Aging; Possible Involvement of the Hippocampal Sirt-1/Nrf2/NF-κB Signaling Pathway
Background: Aging is associated with a wide range of cognitive impairments that affect the quality of life in the elderly. This study aimed to assess the neuroprotective properties of the hydro-alcoholic extract of Melissa officinalis L. (HAEMO) on cognitive impairment mediated by the D-galactose/AlCl₃-induced accelerated aging model. Methods: The C57BL/6 mice were allocated into young and aged control groups, and three aged groups received different doses of HAEMO for 60 days. The performance of mice was assessed using the Lashley III maze and the novel object recognition test to assess cognitive function. Hippocampal tissue was examined not only for oxidative stress indicators (TAC, MDA, GPx and SOD) but also used for estimations of Sirt-1, Nrf2, NF-кB, IL-6, and TNF-α proteins. Results: The results indicated improved spatial and recognition memories in the HAEMO-received aged animals. The behavioral advantages were probably linked to diminished lipid peroxidation, increased antioxidant enzyme activities, and enhancement of the hippocampal Sirt-1/Nrf2 pathway. Moreover, the HAEMO regimen reduced inflammatory markers (NF-κB, TNF-α, and IL-6) in the hippocampus. Conclusion: HAEMO exerts a modulatory effect on the hippocampal Sirt-1/Nrf2/NF-κB pathway, offering a neuroprotective approach against progressive oxidative stress and neuroinflammation that develop with aging. Additional research is necessary to completely understand the therapeutic potential of HAEMO in the preservation of cognition during aging.
- Open Access
- 4 November 2025
- Published by Maad Rayan Publishing Company in Health Promotion Perspectives
- Vol. 15 (3) , 213-235
A systematic review and meta-analysis of the prevalence of post-traumatic stress disorder (PTSD) in road traffic accident survivors
Background: This systematic review and meta-analysis aimed to evaluate the prevalence of post-traumatic stress disorder (PTSD) among road traffic accident (RTA) survivors, a demographic impacted by over 50 million disabilities globally each year. Methods: An initial systematic search was conducted in November 2021, with an updated search performed in October 2024. Relevant databases were comprehensively searched using keywords related to "traffic accidents," "road accidents," "motor vehicle accidents," "PTSD," and "Post-Traumatic Stress Disorder." This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines and the PICO framework established by Cochrane. The review included studies that involved RTA survivors diagnosed with PTSD, focusing on time frames from one to six months post-accident and utilizing DSM criteria. Eligible studies were reviewed for quality using the standardized critical appraisal instruments from the Joanna Briggs Institute (JBI) Checklist, by two independent reviewers. Meta-analysis was performed using Comprehensive Meta-Analysis statistical software and STATA16 to estimate overall prevalence rates and subgroup analyses to explore variations. Results: A comprehensive search across multiple databases identified 11,142 articles, of which 92 were reviewed, and 82 were included in the meta-analysis. The findings revealed an overall PTSD prevalence of 20.3% (95% confidence interval [CI]: 18.1%-22.8%; I2 :93.86%); 18.7% (95% CI: 16.0%-21.8%; I2: 93.47%) based on clinician-administered assessments and 22.8% (95% CI: 18.8%-27.3%; I2: 93.92%) from self-reported questionnaires. After removing outliers, the total prevalence was decreased to 18.1% (95% CI: 15.4%-21.0%; I2 :93.09%), in clinician-administered and 20.8% (95% CI: 17.5%-24.4%; I2 : 91.51%) in self-reported questionnaires. Notably, the prevalence was 29.4% (95% CI: 22.4%-37.5%) one-month post-RTA, decreasing to 18.8% (95% CI: 14.8%-23.5%); P<0.001 at three months. Age did not significantly predict PTSD prevalence rates. The quality assessment of the studies included demonstrated moderate to high quality according to the Joanna Briggs Institute standards, ensuring the reliability of the findings. Geographic variability in PTSD prevalence was observed, with lower rates reported in Switzerland, Australia, Germany, and Japan, while higher rates were found in Spain, China, and Iran. Conclusion: This review highlights a significant PTSD prevalence of 20.3% among traffic accident survivors, emphasizing the need for early intervention and targeted mental health support to mitigate long-term psychological impacts and improve recovery outcomes in this vulnerable population. Screening and public awareness of disease symptoms are recommended.
- 4 November 2025
- Published by Maad Rayan Publishing Company in Health Promotion Perspectives
- Vol. 15 (3) , 213-235
Open AccessA systematic review and meta-analysis of the prevalence of post-traumatic stress disorder (PTSD) in road traffic accident survivors
Background: This systematic review and meta-analysis aimed to evaluate the prevalence of post-traumatic stress disorder (PTSD) among road traffic accident (RTA) survivors, a demographic impacted by over 50 million disabilities globally each year. Methods: An initial systematic search was conducted in November 2021, with an updated search performed in October 2024. Relevant databases were comprehensively searched using keywords related to "traffic accidents," "road accidents," "motor vehicle accidents," "PTSD," and "Post-Traumatic Stress Disorder." This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines and the PICO framework established by Cochrane. The review included studies that involved RTA survivors diagnosed with PTSD, focusing on time frames from one to six months post-accident and utilizing DSM criteria. Eligible studies were reviewed for quality using the standardized critical appraisal instruments from the Joanna Briggs Institute (JBI) Checklist, by two independent reviewers. Meta-analysis was performed using Comprehensive Meta-Analysis statistical software and STATA16 to estimate overall prevalence rates and subgroup analyses to explore variations. Results: A comprehensive search across multiple databases identified 11,142 articles, of which 92 were reviewed, and 82 were included in the meta-analysis. The findings revealed an overall PTSD prevalence of 20.3% (95% confidence interval [CI]: 18.1%-22.8%; I2 :93.86%); 18.7% (95% CI: 16.0%-21.8%; I2: 93.47%) based on clinician-administered assessments and 22.8% (95% CI: 18.8%-27.3%; I2: 93.92%) from self-reported questionnaires. After removing outliers, the total prevalence was decreased to 18.1% (95% CI: 15.4%-21.0%; I2 :93.09%), in clinician-administered and 20.8% (95% CI: 17.5%-24.4%; I2 : 91.51%) in self-reported questionnaires. Notably, the prevalence was 29.4% (95% CI: 22.4%-37.5%) one-month post-RTA, decreasing to 18.8% (95% CI: 14.8%-23.5%); P<0.001 at three months. Age did not significantly predict PTSD prevalence rates. The quality assessment of the studies included demonstrated moderate to high quality according to the Joanna Briggs Institute standards, ensuring the reliability of the findings. Geographic variability in PTSD prevalence was observed, with lower rates reported in Switzerland, Australia, Germany, and Japan, while higher rates were found in Spain, China, and Iran. Conclusion: This review highlights a significant PTSD prevalence of 20.3% among traffic accident survivors, emphasizing the need for early intervention and targeted mental health support to mitigate long-term psychological impacts and improve recovery outcomes in this vulnerable population. Screening and public awareness of disease symptoms are recommended.
- 10 September 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (7) , 264
4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia
Brain ischemia is a major global cause of disability, frequently leading to psychoneurological issues. This study investigates the effects of 4-aminopyridine (4-AP) on anxiety, cognitive impairment, and potential underlying mechanisms in a mouse model of medial prefrontal cortex (mPFC) ischemia. Mice with mPFC ischemia were treated with normal saline (NS) or different doses of 4-AP (250, 500, and 1000 µg/kg) for 14 consecutive days. The open field test, elevated plus maze, Barnes maze, and novel object recognition test were used to perform a series of behavioral assessments to evaluate anxiety as well as spatial and episodic memory. Serum corticosterone levels and changes in oxidative stress markers (MDA, SOD, GPx, and TAC) were measured by ELISA. Inflammatory and apoptotic markers (p-P38, NF-κB, IL-1β, TNF-α, p-PI3K, p-AKT, Caspase-3, BAX, and BCL2) were analyzed via western blotting. Results showed that mPFC ischemia induced anxiety-like behavior and disrupted both recognition and spatial memory at the behavioral level. Additionally, ischemia increased serum corticosterone levels, elevated oxidative stress, and upregulated inflammatory and apoptotic markers. However, 4-AP at the highest dose significantly mitigated these behavioral and molecular deficits. These findings suggest that 4-AP alleviates anxiety-like behavior and cognitive impairment associated with mPFC ischemia, possibly through modulation of corticosterone, oxidative stress, inflammation, and apoptotic signaling pathways.
- 10 September 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (7) , 264
4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia
Brain ischemia is a major global cause of disability, frequently leading to psychoneurological issues. This study investigates the effects of 4-aminopyridine (4-AP) on anxiety, cognitive impairment, and potential underlying mechanisms in a mouse model of medial prefrontal cortex (mPFC) ischemia. Mice with mPFC ischemia were treated with normal saline (NS) or different doses of 4-AP (250, 500, and 1000 µg/kg) for 14 consecutive days. The open field test, elevated plus maze, Barnes maze, and novel object recognition test were used to perform a series of behavioral assessments to evaluate anxiety as well as spatial and episodic memory. Serum corticosterone levels and changes in oxidative stress markers (MDA, SOD, GPx, and TAC) were measured by ELISA. Inflammatory and apoptotic markers (p-P38, NF-κB, IL-1β, TNF-α, p-PI3K, p-AKT, Caspase-3, BAX, and BCL2) were analyzed via western blotting. Results showed that mPFC ischemia induced anxiety-like behavior and disrupted both recognition and spatial memory at the behavioral level. Additionally, ischemia increased serum corticosterone levels, elevated oxidative stress, and upregulated inflammatory and apoptotic markers. However, 4-AP at the highest dose significantly mitigated these behavioral and molecular deficits. These findings suggest that 4-AP alleviates anxiety-like behavior and cognitive impairment associated with mPFC ischemia, possibly through modulation of corticosterone, oxidative stress, inflammation, and apoptotic signaling pathways.
- Open Access
- 1 September 2024
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 15 (5) , 569-582
Ask, and You Shall Receive: A Closer Look on Unsolved Consciousness Issue
There are numerous views about the concept of consciousness, and no consensus exists regarding its meaning. However, the latest neuroscientific developments have eliminated the misleading obstacles related to consciousness. Over the last few decades, neuroscientific efforts in determining the function of the brain and merging these findings with philosophical theories ...
- 1 September 2024
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 15 (5) , 569-582
Open AccessAsk, and You Shall Receive: A Closer Look on Unsolved Consciousness Issue
There are numerous views about the concept of consciousness, and no consensus exists regarding its meaning. However, the latest neuroscientific developments have eliminated the misleading obstacles related to consciousness. Over the last few decades, neuroscientific efforts in determining the function of the brain and merging these findings with philosophical theories ...
- 30 March 2024
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 21 (4) , 521-535
Magnetic hybrid nanovesicles for the precise diagnosis and treatment of central nervous system disorders
1. The mean global lifetime risk of central nervous system (CNS) disorders, such as brain infections, Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s disease (PD), transmissible en...
- 30 March 2024
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 21 (4) , 521-535
Magnetic hybrid nanovesicles for the precise diagnosis and treatment of central nervous system disorders
1. The mean global lifetime risk of central nervous system (CNS) disorders, such as brain infections, Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s disease (PD), transmissible en...
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 19 (2) , 185-199
Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?
Parkinson's disease (PD) is a common, progressive neurodegenerative disorder characterized by substantia nigra dopamine cell death and a varied clinical picture that affects older people. Although more than two centuries have passed since the earliest attempts to find a cure for PD, it remains an unresolved problem. With this in mind, cell replacement therapy is a new strategy for treating PD. This novel approach aims to replace degenerated dopaminergic (DAergic) neurons with new ones or provide a new source of cells that can differentiate into DAergic neurons. Induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), and embryonic stem cells (ESCs) are among the cells considered for transplantation therapies. Recently disease-modifying strategies like cell replacement therapies combined with other therapeutic approaches, such as utilizing natural compounds or biomaterials, are proposed to modify the underlying neurodegeneration. In the present review, we discuss the current advances in cell replacement therapy for PD and summarize the existing experimental and clinical evidence supporting this approach.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 19 (2) , 185-199
Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?
Parkinson's disease (PD) is a common, progressive neurodegenerative disorder characterized by substantia nigra dopamine cell death and a varied clinical picture that affects older people. Although more than two centuries have passed since the earliest attempts to find a cure for PD, it remains an unresolved problem. With this in mind, cell replacement therapy is a new strategy for treating PD. This novel approach aims to replace degenerated dopaminergic (DAergic) neurons with new ones or provide a new source of cells that can differentiate into DAergic neurons. Induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), and embryonic stem cells (ESCs) are among the cells considered for transplantation therapies. Recently disease-modifying strategies like cell replacement therapies combined with other therapeutic approaches, such as utilizing natural compounds or biomaterials, are proposed to modify the underlying neurodegeneration. In the present review, we discuss the current advances in cell replacement therapy for PD and summarize the existing experimental and clinical evidence supporting this approach.